International journal of cancer and oncology最新文献

Expression of HDAC8 indicates poor prognosis of esophageal squamous cell carcinoma and progression to advanced stage HDAC8的表达预示着食管鳞状细胞癌预后不良，进展到晚期

International journal of cancer and oncology Pub Date : 2019-06-26 DOI: 10.15436/2377-0902.19.2465

Y. Cheng, E. Nesa, Xuan Chen, Cong Wang, Xue Chen, Yuan Wang, Y. Qu, S. Mi, Shanghai Guan, Tamanna Zahur, Fengxia Xiao, Ommega Internationals

{"title":"Expression of HDAC8 indicates poor prognosis of esophageal squamous cell carcinoma and progression to advanced stage","authors":"Y. Cheng, E. Nesa, Xuan Chen, Cong Wang, Xue Chen, Yuan Wang, Y. Qu, S. Mi, Shanghai Guan, Tamanna Zahur, Fengxia Xiao, Ommega Internationals","doi":"10.15436/2377-0902.19.2465","DOIUrl":"https://doi.org/10.15436/2377-0902.19.2465","url":null,"abstract":"Background: We determined to assess the HDAC8 expression in esophageal squamous cell carcinoma (ESCC) patients and prognostic potential though there is only a little research contribution regarding HDAC8 to tumorigenesis of ESCC.\u0000Methods: The immunohistochemical expression of HDAC8 was investigated on tissue microarrays (TMAs) from 110 patients with esophageal squamous cell carcinoma.The nuclear staining intensity is calculated by the immune reactivity score ranging from (0-12) and divides them into two groups: no expression group and overexpression.\u0000Results: The median follow-up duration was 70 months. Highly regulated HDAC8 protein significantly predicted decreased 5-year overall survival (p = 0.001) and progression-free survival (p = 0.001) demonstrated by the log-rank test. Furthermore, HDAC8 protein acts as an independent prognostic factor for overall survival and progression-free survival, which determined after multivariate analyses. By Receiver operating characteristics (ROC) analysis, the value of HDAC8 was (0.63±0.54,p=0.04) according to advance cancer stage and (0.59±0.06,p=0.04) according to the lymph node status found in the Area under the curve (AUC).\u0000Conclusion: HDAC8 protein is highly regulated in ESCC tissues and potential prognostic indicator for diagnosing patients with decreased survival period.","PeriodicalId":91089,"journal":{"name":"International journal of cancer and oncology","volume":" 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41253962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lymphomatoid Granulomatosis: Rare Radiologic Presentation as a Solitary Pulmonary Mass 类淋巴瘤肉芽肿病:罕见的影像学表现为孤立的肺部肿块

International journal of cancer and oncology Pub Date : 2019-03-25 DOI: 10.15436/2377-0902.19.2440

A. Shestakova, N. Gallegos, B. Wang, Bosemani Thangavijayan, Ommega Internationals

{"title":"Lymphomatoid Granulomatosis: Rare Radiologic Presentation as a Solitary Pulmonary Mass","authors":"A. Shestakova, N. Gallegos, B. Wang, Bosemani Thangavijayan, Ommega Internationals","doi":"10.15436/2377-0902.19.2440","DOIUrl":"https://doi.org/10.15436/2377-0902.19.2440","url":null,"abstract":"Background: Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven lymphoproliferative disease. LYG is characterized by a progressive clinical course, which virtually always involves the lungs. LYG characteristically presents as bilateral pulmonary nodules. Pathologically, it is characterized by an angiocentric and angiodestructive infiltration of atypical EBV-positive B-lymphocytes admixed with reactive T-lymphocytes. We report a case of pulmonary LYG that presented as a large mass with complete occlusion of the right main stem bronchus intermedius in an 81-year-old female. Case: An 81-year-old female presented with shortness of breath to the emergency department. Inpatient imaging revealed bulky mediastinal lymphadenopathy with a right lower lobe collapse, shift of the cardiomediastinal silhouette, and a large right upper lung mass. Endobronchial ultrasound-guided biopsy (EBUS) revealed complete occlusion of right mainstem bronchus due to the right upper lung mass growth into the bronchus intermedius. Histopathological examination demonstrated clusters of large atypical EBV-positive B cells interspersed in a minimally polymorphous lymphocytic background, consistent with lymphomatoid granulomatosis, grade 3/3. Patient was treated with immunochemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone - CHOP) and Rituximab (anti-CD20 antibody). At the patient’s most recent follow-up, 6 months later, she was in a stable condition and her respiratory symptoms have improved. Conclusion: Lymphomatoid granulomatosis is a rare disease that should be considered in the differential diagnosis of a radiographic evaluation of a solitary pulmonary lung mass. Since the radiographic impression might favor carcinoma as the top differential diagnosis, biopsy of the lesion is paramount to ensure the correct diagnosis. Lymphomatoid granulomatosis is usually treated with an immunochemotherapy regimen with CHOP, and/or interferon, and Rituximab.","PeriodicalId":91089,"journal":{"name":"International journal of cancer and oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43327567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming Barriers to Lung Cancer Screening by Implementing a Single-Visit Patient Experience. 通过实施单次就诊患者体验克服肺癌筛查障碍。

International journal of cancer and oncology Pub Date : 2017-01-01 Epub Date: 2017-05-17 DOI: 10.15436/2377-0902.17.1469

Cherie P Erkmen, Ryan F Moore, Clifford Belden, Verdi DiSesa, Larry R Kaiser, Grace X Ma, Anuradha Paranjape

{"title":"Overcoming Barriers to Lung Cancer Screening by Implementing a Single-Visit Patient Experience.","authors":"Cherie P Erkmen, Ryan F Moore, Clifford Belden, Verdi DiSesa, Larry R Kaiser, Grace X Ma, Anuradha Paranjape","doi":"10.15436/2377-0902.17.1469","DOIUrl":"https://doi.org/10.15436/2377-0902.17.1469","url":null,"abstract":"In 2011 the authors of the National Lung Screening Trial (NLST) reported a 20% risk reduction of lung cancer death using annual screening with a low dose CT (LDCT)[1]. In 2013, the United States Preventative Services Task Force (USPSTF) gave lung cancer screening a grade B recommendation indicating that LDCT should be covered by private insurers without cost sharing (co-pay)[2]. Implementation of a screening program could potentially avert 12,000 deaths annually[3]. Unfortunately, implementation of lung cancer screening programs has been slower than expected. Despite evidence that USPSTF recommendations influence 88.4% of practicing primary care providers (PCP’s)[4], only 47% of PCPs acknowledged the lung cancer screening recommendation[5], and only 12% of PCPs in an academic setting used LDCT scan for lung cancer screening[6]. The reasons for the failure to generate enthusiasm to implement lung cancer screening are multifactorial. However, lung cancer screening provides an opportunity to design novel patient-centered care. In this discussion, we will explore both the barriers to lung cancer screening implementation and our multidisciplinary approach which prioritizes patient-centered care by creating a single-visit patient experience.","PeriodicalId":91089,"journal":{"name":"International journal of cancer and oncology","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796669/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35794066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Protection Against Dimethylbenz[a] Anthracene-Induced Breast Cancer in Female Rats by α-Lactalbumin. α-乳白蛋白对二甲基苯并[a]蒽诱发的雌性大鼠乳腺癌的保护作用

International journal of cancer and oncology Pub Date : 2016-01-01 Epub Date: 2016-02-24 DOI: 10.15436/2377-0902.16.026

Somdutta Sinha Roy, Shyamali Mukherjee, Billy R Ballard, Salil K Das

{"title":"Protection Against Dimethylbenz[a] Anthracene-Induced Breast Cancer in Female Rats by α-Lactalbumin.","authors":"Somdutta Sinha Roy, Shyamali Mukherjee, Billy R Ballard, Salil K Das","doi":"10.15436/2377-0902.16.026","DOIUrl":"10.15436/2377-0902.16.026","url":null,"abstract":"<p><p>Consumption of α-lactalbumin as dietary protein offers a beneficial effect on breast cancer development. Breast cancer was developed by gavage administration of single dose of dimethylbenz(a)anthracene (DMBA) in female rats, maintained on AIN-76A diet with either 20% casein or α-lactalbumin (a component of whey protein). All tumors were detected by palpation. After approximately 130 days of DMBA administration, the animals were euthanized. There was a delay in the development of breast tumor in the α-lactalbumin group in comparison to the casein group. The number of tumors per rat was less in the α-lactalbumin group than that in the casein group at any time point up to 130 days after DMBA administration. Also the incidence of tumors and tumor volume was less in the α-lactalbumin group than those in the casein group. The casein group had a mixture of grade I, grade II and grade III tumors whereas the α-lactalbumin group had mostly grade I tumor. Furthermore, the proliferative index was significantly lower in the α-lactalbumin group than that in the casein group.</p>","PeriodicalId":91089,"journal":{"name":"International journal of cancer and oncology","volume":"3 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978184/pdf/nihms764451.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34751648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiologic and Clinical Profiles of Breast Diseases in Niger 尼日尔乳腺疾病的流行病学和临床概况

International journal of cancer and oncology Pub Date : 2015-07-17 DOI: 10.15436/2377-0902.15.015

Harouna Zouladeny, I. Dillé, N. Wehbi, Jungyoon Kim, A. Soliman

{"title":"Epidemiologic and Clinical Profiles of Breast Diseases in Niger","authors":"Harouna Zouladeny, I. Dillé, N. Wehbi, Jungyoon Kim, A. Soliman","doi":"10.15436/2377-0902.15.015","DOIUrl":"https://doi.org/10.15436/2377-0902.15.015","url":null,"abstract":"This study aimed at characterizing epidemiologic and clinical profiles of breast diseases in Niger during the period of 2010–2013 at the National Hospital of Niamey. Medical records were abstracted for demographic, reproductive, clinical, and treatment information. A process map of patient navigation and barriers to seeking medical care was developed after interviewing 26 local health professionals who encounter and/or manage breast diseases. We identified 245 breast cancers and 122 other breast diseases. Mean age of breast cancer patients was 45.4 (±13.26 years) and that of breast diseases was 31(±12.5 years) with 1/3 of cancers under age 44. Infection-related diseases represented 24% of non-cancers. Male breast diseases represented 4.75% of diseases and 2.05% of cancers. Only 37.1% of cancers had histopathologic confirmation and 90% of cancer patients presented at advanced stages and mastectomy was performed for 66% of breast cancers. Patient and system barriers to care were common in diagnosing and treating breast diseases. Women in Niger have double burden of infectious breast diseases and emerging breast cancer. Younger age and late diagnosis are common features. Reducing barriers to access to care, down-staging of cancer, implementation of clinical guidelines for managing advanced cases are important needs for reducing breast cancer morbidity and mortality in Niger.","PeriodicalId":91089,"journal":{"name":"International journal of cancer and oncology","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67677970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Multiple Pathways Control the Reactivation of Telomerase in HTLV-I-Associated Leukemia. 多途径控制htlv - i相关白血病端粒酶的再激活。

International journal of cancer and oncology Pub Date : 2015-06-02 DOI: 10.15436/2377-0902.15.017

Marcia Bellon, Christophe Nicot

引用次数: 10